

For Immediate Release

SZ Pharmaceutical appoints Cannabis and Hemp Pioneer Calvin Frye to its Board of Directors.

SZ Pharmaceutical, the pharmaceutical wing of Solomon Zambia Group, with its fully approved and authorized medical, recreational, and consumer cannabis license allows the cultivation, production, manufacturing, and distribution rights of low (<0.2%) and high (>0.2%) THC products in Greece. This includes the import and export of low-THC products such as CBD, natural wellness products, cosmetics, food supplements, novel foods, and high-THC products."

Bob Sapp, an American sports and acting icon who has been newly appointed as the CEO of all Solomon Zambia group of companies, stated, "Working alongside Calvin Frye is not just a partnership; it's a mission to redefine how we view cannabis in healthcare. His unwavering dedication to patient rights and advocacy inspires me. Together, at SZ Pharmaceutical, we're not just creating a new pharmaceutical venture—we're championing a movement that empowers individuals to reclaim their health and well-being through safe, accessible cannabis and pharmaceutical solutions."

SZ Pharmaceutical acquired control of [Euro Pacific Hellas Group](#), which holds one of the few licenses for medical cannabis and experimental pharmaceutical products in Greece. Calvin Frye stated, "I look forward to bringing my 20+ years of cannabis and hemp experience to this company to really push the boundaries of what cannabis and hemp products can do in the realm of alternative medicine."

Calvin Frye

Scientist, pioneering cannabis activist, entrepreneur, and Multistate Operator (MSO) business license holder, Calvin Frye has over 18 years of experience as a dispensary owner and Medical Marijuana (MMJ) industry consultant. He served on the advisory board for the Cannabis World Congress & Business Exposition, was the CEO of Le Global, a publicly traded cannabis company, and is currently the chairman of the SESC (Social Equity Standing Committee) of the National Hemp Association. Mr. Frye has held several key positions in the Biotech industry for major companies like Xoma, Amgen, and Baxter Biosciences, advancing his career from Research Associate to Associate Scientist. Mr. Frye has invaluable experience working alongside some of the founders of the MMJ industry as well as many of the industry pioneering groups in Los Angeles (Americans for Safe Access and Norml).

Mr. Frye has one of the oldest cannabis licenses in Los Angeles and is one of the first dispensary owners in the entire country. He has been pivotal in the progression of the cannabis movement throughout the United States. As an activist, Mr. Frye travels all over the United

States to help shape and pass current MMJ legislation. He has appeared in numerous documentaries and television shows and has been featured in many magazines as one of the premier voices in cannabis. Nationally, Mr. Frye has been the featured speaker at many conferences including the Cannabis World Congress & Business Expo, Blunt Talks, etc. Mr. Frye has first-hand knowledge of the regulatory issues affecting the cannabis industry through his extensive work with local LA government bodies and agencies. Mr. Frye has also branded his line of cannabis genetics and trademarked the name "Cloneville" which he has attached to his genetics. In 2009, Mr. Frye consulted in the hydroponics industry where he gained extensive knowledge in the actual growing, setup, and production of cannabis.

Mr. Frye earned his Bachelor of Science degree from the University of Iowa (Big Ten Conference) in Science Education. He also attended graduate college with an emphasis in General Science.

SZ Pharmaceutical has a **privately owned area of 44,500 m² (11 acres) in the valley of Karditsa, Greece** in which to grow and manufacture cannabis products for distribution in Greece, as well as the EU. The company has an extensive distribution system across approximately 12,000 pharmacies to distribute products medicinally. In conjunction with universities in Greece and abroad, this company has the ability to do clinical trials on its products to prepare them for the market.

About SZ Pharmaceutical

SZ Pharmaceutical is a pharmaceutical company that plans to expand in the Psychedelics, Hemp, and Cannabis industries. The company is refocusing its purpose on the development, research, and commercialization of products derived from Psychedelics, Hemp, and Cannabis Plants.

Disclaimer: The Company relies on the Safe Harbor provisions of the Securities Act of 1933, the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The Company, through its management, makes forward-looking public statements concerning its expected future operations, performance, and other developments. Such forward-looking statements are estimates based on the company's best judgment using current information and involve various risks and uncertainties. There can be no assurance that factors not currently known will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors that could cause actual results to differ materially from those estimated by the Company which include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, and other factors that may be identified from time to time in the company's public announcements.

Contact:

Alex Mentora

alex@mentorafamily.com